Evidence map›Paper›PMID 33632157›Full record

ArticleBMC cancer2021

Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.

Libo Yu, Qingtao Shi, Yan Jin, Zhixin Liu, Jiaxin Li, Wenzhou Sun

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. CLDN6 induces chemoresistance through protective autophagy in breast cancer.International journal of biological sciences · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Libo YuMedicine Department, Harbin Medical University Cancer Hospital, Haping Road No.150, Harbin, 150081, Heilongjiang, China.
Qingtao ShiMedicine Department, Harbin Medical University Cancer Hospital, Haping Road No.150, Harbin, 150081, Heilongjiang, China.
Yan JinMedicine Department, Harbin Medical University Cancer Hospital, Haping Road No.150, Harbin, 150081, Heilongjiang, China.
Zhixin LiuMedicine Department, Harbin Medical University Cancer Hospital, Haping Road No.150, Harbin, 150081, Heilongjiang, China.
Jiaxin LiMedicine Department, Harbin Medical University Cancer Hospital, Haping Road No.150, Harbin, 150081, Heilongjiang, China.
Wenzhou SunMedicine Department, Harbin Medical University Cancer Hospital, Haping Road No.150, Harbin, 150081, Heilongjiang, China. sunwenzhou001111@163.com.ORCID http://orcid.org/0000-0002-4251-1154
Harbin Medical University · CN

Funding

Science and Technology Research Project of Heilongjiang Education Department 10541144; 12531275
6 · The paper itself

Abstract

backgroundActivation of autophagy flux contributed to resistance of breast cancer (BC) cells to current chemotherapeutic drugs, which seriously limited their therapeutic efficacy and facilitated BC recurrence in clinic. However, the detailed mechanisms are still not fully understood. In the present study, we identified that inactivation of AMPK-ULK1 signaling cascade mediated protective autophagy sensitized BC cells to doxorubicin in vitro.

methodsCell counting kit-8 (CCK-8) assay and colony formation assay were performed to evaluate cell proliferation abilities. Trypan blue staining assay was used to examine cell viability, and Annexin V-FITC/PI double staining method was conducted to determine cell apoptosis. The autophagosomes in BC cells were observed and photographed by electronic microscope (EM). Western Blot analysis was employed to examine genes expressions at protein levels.

resultsThe parental doxorubicin-sensitive BC (DS-BC) cells were exposed to increasing concentrations of doxorubicin to establish doxorubicin-resistant BC (DR-BC) cells, and the DR-BC cells were much more resistant to high-dose doxorubicin treatment compared to the DS-BC cells. Interestingly, high-dose doxorubicin specifically increased LC3B-II/I ratio, promoted autophagosomes formation and decreased p62 expression levels to facilitate autophagy in DR-BC cells, instead of DS-BC cells, and the autophagy inhibitor 3-methyladenine (3-MA) enhanced the cytotoxic effects of high-dose doxorubicin on DR-BC cells. In addition, we proved that high-dose doxorubicin triggered protective autophagy in DR-BC cells by activating AMPK-ULK1 pathway. Functionally, high-dose doxorubicin increased the expression levels of phosphorylated AMPK (p-AMPK) and ULK1 (p-ULK1) to activate AMPK-ULK1 pathway in DR-BC cells, and the inhibitors for AMPK (compound C) and ULK1 (SBI-0206965) blocked autophagy to promote cell death and slow down cell growth in DR-BC cells treated with high-dose doxorubicin.

conclusionsCollectively, our in vitro data indicated that blockage of AMPK-ULK1 signaling cascade mediated protective autophagy might be a promising strategy to increase doxorubicin sensitivity for BC treatment.

Indexed as

AdenineAMP-Activated Protein KinasesApoptosisAutophagyAutophagy-Related Protein-1 HomologBreast NeoplasmsCell Line, TumorDoxorubicinDrug Resistance, NeoplasmFemaleHumansIntracellular Signaling Peptides and ProteinsSignal Transduction3-methyladenineAdenineAMP-Activated Protein KinasesAutophagy-Related Protein-1 HomologDoxorubicinIntracellular Signaling Peptides and ProteinsULK1 protein, humanAMPK-ULK1 signal pathwayAutophagyBreast cancerChemo-resistanceDoxorubicin

Identifiers

PMID33632157
PMCPMC7905888
OpenAlexW3130583765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.